Activity Description
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Explore the 3-part on-demand series, Shedding Light on Type 2 Diabetes: Weight Management & Future Breakthroughs. This collaborative effort, in conjunction with local AAFP Chapter meetings, provides expert guidance and clinical best practices to understand the impact of weight on T2D outcomes, weight management as a treatment for T2D, and effective strategies for shared decision-making in T2D care. Key topics in Part 2: Weight Management as a Treatment for T2D: Novel Pharmacological Approaches include:
- Mechanistic drivers of T2D pathophysiology and the role of emerging treatment options: Review. How incretin-based drugs’ mechanism of action is effective in treating patients with T2D, with a focus on disease pathophysiology
- Evidence-based approaches in the treatment of T2D in accordance with ADA/EASD guidelines: Assess. Both current standards of care in T2D and the latest clinical evidence of new and emerging incretin-based treatments
Don't miss the opportunity to join this series and learn in person, gaining valuable insights into effectively addressing T2D for improved patient health. Be sure to take part 2 and part 3 to maximize your education and impact!
-
Part 1: Understanding the Impact of Weight on T2D Outcomes
This activity covers the risks of excess weight among patients with T2D and investigates the intricate relationship between weight, obesity, and T2D -
Part 3: Effective Strategies for Shared Decision-Making in T2D Care
This activity covers finding value in shared decision-making and the unique role of multidisciplinary teams
Speakers
Chuck Vega, MD
Clinical Professor, UC Irvine
Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Santa Ana, CA, USA
Chuck grew up in Northern California and completed his undergraduate degree at Harvard University. He attended medical school at the University of Wisconsin – Madison and completed residency training in Family Medicine at UC Irvine. He stayed on as faculty in the Department of Family Medicine at UCI and now holds the title of Health Sciences Clinical Professor. He is the Director of UCI’s Program in Medical Education for the Latino Community and won a Macy Faculty Scholarship to improve patient-centered health education at UCI. He currently serves as Assistant Dean for Culture and Community Education in the UC Irvine School of Medicine.
Dr. Vega has seen patients and taught medical students and residents at UC Irvine’s Family Health Center – Santa Ana for the past 27 years. This clinic is a federally-qualified health center and the largest safety-net clinic for Orange County. Dr. Vega’s academic interests are focused on access to quality, compassionate medical care for underserved populations, and the development of training programs to promote this vision of healthcare.
Martin J. Abrahamson, MD, FACP
Associate Professor of Medicine
Harvard Medical School
Boston, MA, USA
Martin J. Abrahamson, MD, is associate professor of medicine at Harvard Medical School, director of the Division of Continuing Medical Education in the Department of Medicine, and an active faculty member of the Endocrine Division, Department of Medicine at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He received his medical degree from University of Cape Town in South Africa and completed his internship, residency, and clinical fellowship in internal medicine and endocrinology at Groote Schuur Hospital in Cape Town, where he was a research fellow before joining the faculty of medicine at the University of Cape Town and Groote Schuur Hospital. Dr. Abrahamson was joint head of the Endocrine Unit in Cape Town before taking up a faculty appointment at Harvard Medical School and Beth Israel Hospital in 1992. He joined the faculty at Joslin Diabetes Center in 1998, where he held positions as Chief of Adult Diabetes, Chief Medical Officer, and Senior Vice President for Medical Affairs until 2015. While at Joslin Diabetes Center, Dr. Abrahamson led the reorganization of the Adult Diabetes Section into multidisciplinary teams comprised of physicians, nurse practitioners, nurse educators, nutritionists, and exercise physiologists and spearheaded “pathways of care” for patients referred to Joslin (JoslinCare). He has co-authored guidelines for the pharmacological and perioperative management of patients with diabetes and management of hyperglycemic emergencies and authored more than 80 papers, review articles, and chapters related to diabetes. Dr. Abrahamson’s research interests include the management of patients with diabetes and use of technology to improve diabetes care and outcomes. Dr. Abrahamson is board certified in endocrinology, diabetes and metabolism and is a fellow of the College of Physicians of South Africa. He has been cited regularly in Boston Magazine as one of Boston’s top doctors, and he has delivered numerous invited lectures nationally and internationally on the management of diabetes. In 2010, he was the recipient of the Samuel Eichold II Memorial Award for contributions to Diabetes from the American College of Physicians.
Accreditation and Disclosure Information
Educational Objectives
After completing this activity, the participant should be better able to:
- Consistently employ the latest clinical data and mechanisms of action for new and emerging treatment options for T2D, including GLP-1RAs and GIP/GLP-1RAs when developing comprehensive treatment plans
Program Agenda
- Mechanistic drivers of T2D pathophysiology and the role of emerging treatment options
- Evidence-based approaches in the treatment of T2D in accordance with ADA/EASD guidelines
Target Audience
This activity is directed towards U.S. primary care physicians, NPs, and PAs including those who are community-based, practice in large ACOs; in rural communities; and who serve patients in underserved areas.
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AAFP CME Credit
The AAFP has reviewed Shedding Light on Type 2 Diabetes: Weight Management & Future Breakthroughs | Weight Management as a Treatment for T2D: Novel Pharmacological Approaches and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 04/30/2024 to 04/30/2025. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
Physician Associate
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until October 31, 2025. PAs should only claim credit commensurate with the extent of their participation
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Commercial Support
Statement This activity is supported by an educational grant from Eli Lilly and Company.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc. is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Chair/Planner/Presenter
Chuck Vega, MD
Clinical Professor, UC Irvine Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Santa Ana, CA, USA
Chuck Vega, MD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: GlaxoSmithKline, Boehringer Ingelheim
Planner/Presenter
Martin J. Abrahamson, MD, FACP
Associate Professor of Medicine
Harvard Medical School
Boston, MA, USA
Martin J. Abrahamson, MD, FACP, has a financial interest/relationship or affiliation in the form of:
The following relationships have ended within the last 24 months:
Advisory Board/Consultant: WebMD Health Services (ended December, 2023)
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and the activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact via email at mvu@mlieducation.org.
For Physicians, if requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2024 Medical Learning Institute, Inc. All Rights Reserved.